Citigroup Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $145

Benzinga Newsdesk www.benzinga.com Positive 54.0%

Neg 0% Neu 0% Pos 54%

Citigroup analyst Yigal Nochomovitz initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Price Target of $145.